UCB is launching Make HStory, an educational campaign that provides tools and resources for those living with hidradenitis suppurativa (HS) and their dermatologists.
By encouraging patient and dermatologist conversations, Make HStory aims to help increase understanding of the disease and empower patients to have conversations with their dermatologist about management options.
The U.S. Food and Drug Administration (FDA) recently accepted the supplemental Biologics License Application (sBLA) for bimekizumab-bkzx (Bimzelx, UCB), an interleukin(IL)-17A and IL-17F inhibitor, for the treatment of adults with moderate-to-severe hidradenitis suppurativa (HS).
In addition, a second sBLA for the Bimzelx 2mL device presentations has also been accepted, according to UCB.
“My hope for Make HStory is that it can empower people who have lived with HS in silence or without answers to seek out the support they may need and visit a dermatologist to discuss the optimal care plan,” says Brittany Blair, U.S. Immunology Patient Strategy lead, UCB in a news story. “My UCB colleagues and I are incredibly grateful to those who have already shared their HS journeys and stories as part of the Make HStory campaign. Their own experiences and personal histories are what will provide hope and a path forward for so many others.”
This new campaign features stories of those living with HS, informational videos, and interactive tools and resources for those seeking management options, daily care, and information about HS. The patient campaign was created as a partner to the previously launched Make HStory medical education campaign, and features educational information, downloadable resources, a strong online and streaming service video presence, and social media, including Instagram and Facebook.
“The Make HStory disease-state education campaign is a testament to UCB’s commitment to improving the lives of millions of people living with inflammatory diseases, like HS,” says Camille Lee, Head of U.S. Immunology, UCB. “Engaging both dermatologists and patients with information about HS helps ensure that key facts critical to improving diagnostics, care, and management can be incorporated in patient care, whether raised by a patient or their provider.”
